Second, the IDO- BMSC may start expressing IDO when exposed to an inflammatory milieu enriched in IFN-γ, implying that the immune resistance mechanisms centered on IDO could be exploited in vivo both by the myeloma cells and by microenvironmental cell types, such as BMSC. Here, IDO1 is linked to plasma cell myeloma.